The somatostatin receptor subtype 5 in neuroendocrine tumours

Bibliography

• Brazeau P, Vale W, Burgus R, Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179(68):77-9
   PubMed Web of Science ®Google Scholar
• Hoyer D, Bell GI, Berelowitz M, Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995;16(3):86-8
   PubMed Web of Science ®Google Scholar
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16(4):427-42
   PubMed Web of Science ®Google Scholar
• Yamada Y, Post SR, Wang K, Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 1992;89(1):251-5
   PubMed Web of Science ®Google Scholar
• Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta 2003;1616(1):1-84
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van der Lely AJ, Hofland LJ. New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol 2002;146(5):701-5
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20(3):157-98
   PubMed Web of Science ®Google Scholar
• Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87(7):3013-8
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334(4):246-54
   PubMed Web of Science ®Google Scholar
• Shimon I. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 2003;20(3):265-70
   PubMed Web of Science ®Google Scholar
• Shimon I, Taylor JE, Dong JZ, Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997;99(4):789-98
   PubMed Web of Science ®Google Scholar
• Shimon I, Yan X, Taylor JE, Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997;100(9):2386-92
   PubMed Web of Science ®Google Scholar
• Saveanu A, Morange-Ramos I, Gunz G, A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies. Eur J Endocrinol 2001;145(1):35-41
   PubMed Web of Science ®Google Scholar
• Saveanu A, Gunz G, Dufour H, Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86(1):140-5
   PubMed Web of Science ®Google Scholar
• Rohrer SP, Birzin ET, Mosley RT, Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998;282(5389):737-40
   PubMed Web of Science ®Google Scholar
• Rohrer SP, Schaeffer JM. Identification and characterization of subtype selective somatostatin receptor agonists. J Physiol Paris 2000;94(3-4):211-5
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146(5):707-16
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002;143(10):4123-30
   PubMed Web of Science ®Google Scholar
• Lewis I, Bauer W, Albert R, A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 2003;46(12):2334-44
   PubMed Web of Science ®Google Scholar
• Ma P, Wang Y, van der Hoek J, Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 2005;78(1):69-80
   PubMed Web of Science ®Google Scholar
• Culler MD. Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. Dig Liver Dis 2004;36(Suppl 1):S17-25
   PubMedGoogle Scholar
• Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides 2001;35(1):1-23
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24(1):28-47
   PubMed Web of Science ®Google Scholar
• Patel YC, Greenwood MT, Panetta R, The somatostatin receptor family. Life Sci 1995;57(13):1249-65
   PubMed Web of Science ®Google Scholar
• Schonbrunn A. Somatostatin receptors present knowledge and future directions. Ann Oncol 1999;10(Suppl 2):S17-21
   PubMed Web of Science ®Google Scholar
• Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996;137(9):4046-9
   PubMed Web of Science ®Google Scholar
• Jacobs S, Schulz S. Intracellular trafficking of somatostatin receptors. Mol Cell Endocrinol 2008;286(1-2):58-62
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Wawrowsky KA, Proekt I, Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 2005;280(25):24011-21
   PubMed Web of Science ®Google Scholar
• Sarret P, Nouel D, Dal Farra C, Receptor-mediated internalization is critical for the inhibition of the expression of growth hormone by somatostatin in the pituitary cell line AtT-20. J Biol Chem 1999;274(27):19294-300
   PubMed Web of Science ®Google Scholar
• Peverelli E, Lania AG, Mantovani G, Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop. Endocrinology 2009;150(7):3169-76
   PubMed Web of Science ®Google Scholar
• Peverelli E, Mantovani G, Calebiro D, The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation. Mol Endocrinol 2008;22(3):676-88
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28(7):836-46
   PubMedGoogle Scholar
• Kumar U, Sasi R, Suresh S, Subtype-selective expression of the five somatostatin receptors (hSSTR1- 5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999;48(1):77-85
   PubMed Web of Science ®Google Scholar
• Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12(4):450-82
   PubMed Web of Science ®Google Scholar
• Heaney AP, Melmed S. Molecular targets in pituitary tumours. Nat Rev Cancer 2004;4(4):285-95
   PubMed Web of Science ®Google Scholar
• Jaquet P, Saveanu A, Gunz G, Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000;85(2):781-92
   PubMed Web of Science ®Google Scholar
• Corleto VD, Falconi M, Panzuto F, Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology 2009;89(2):223-30
   PubMed Web of Science ®Google Scholar
• O'Toole D, Saveanu A, Couvelard A, The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol 2006;155(6):849-57
   PubMed Web of Science ®Google Scholar
• Papotti M, Bongiovanni M, Volante M, Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440(5):461-75
   PubMed Web of Science ®Google Scholar
• Pasquali D, Rossi V, Conzo G, Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 2008;40(6):263-71
   PubMed Web of Science ®Google Scholar
• Sarret P, Esdaile MJ, McPherson PS, Role of amphiphysin II in somatostatin receptor trafficking in neuroendocrine cells. J Biol Chem 2004;279(9):8029-37
   PubMed Web of Science ®Google Scholar
• Tulipano G, Stumm R, Pfeiffer M, Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004;279(20):21374-82
   PubMed Web of Science ®Google Scholar
• Stroh T, Jackson AC, Sarret P, Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology 2000;141(1):354-65
   PubMed Web of Science ®Google Scholar
• Sharif N, Gendron L, Wowchuk J, Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 2007;148(5):2095-105
   PubMed Web of Science ®Google Scholar
• Rocheville M, Lange DC, Kumar U, Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000;288(5463):154-7
   PubMed Web of Science ®Google Scholar
• Rocheville M, Lange DC, Kumar U, Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000;275(11):7862-9
   PubMed Web of Science ®Google Scholar
• Grant M, Alturaihi H, Jaquet P, Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 2008;22(10):2278-92
   PubMed Web of Science ®Google Scholar
• Lesche S, Lehmann D, Nagel F, Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009;94(2):654-61
   PubMed Web of Science ®Google Scholar
• Schonbrunn A. Selective agonism in somatostatin receptor signaling and regulation. Mol Cell Endocrinol 2008;286(1-2):35-9
   PubMed Web of Science ®Google Scholar
• Cescato R, Schulz S, Waser B, Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006;47(3):502-11
   PubMed Web of Science ®Google Scholar
• Attanasio R, Baldelli R, Pivonello R, Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 2003;88(11):5258-65
   PubMed Web of Science ®Google Scholar
• Bevan JS, Atkin SL, Atkinson AB, Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87(10):4554-63
   PubMed Web of Science ®Google Scholar
• Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003;58(4):387-99
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, van Koetsveld PM, The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004;89(4):1577-85
   PubMed Web of Science ®Google Scholar
• Murray RD, Kim K, Ren SG, The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89(6):3027-32
   PubMed Web of Science ®Google Scholar
• van der Hoek J, de Herder WW, Feelders RA, A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89(2):638-45
   PubMed Web of Science ®Google Scholar
• Ballare E, Persani L, Lania AG, Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001;86(8):3809-14
   PubMed Web of Science ®Google Scholar
• Lania A, Mantovani G, Spada A. Genetic abnormalities of somatostatin receptors in pituitary tumors. Mol Cell Endocrinol 2008;286(1-2):180-6
   PubMed Web of Science ®Google Scholar
• Filopanti M, Ronchi C, Ballare E, Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 2005;90(8):4824-8
   PubMed Web of Science ®Google Scholar
• Taboada GF, Luque RM, Neto LV, Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008;158(3):295-303
   PubMed Web of Science ®Google Scholar
• Atkinson AB, Kennedy A, Wiggam MI, Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005;63(5):549-59
   PubMed Web of Science ®Google Scholar
• de Bruin C, Feelders RA, Lamberts SW, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s syndrome. Rev Endocr Metab Disord 2009;10(2):91-102
   Google Scholar
• van der Hoek J, Lamberts SW, Hofland LJ. The role of somatostatin analogs in Cushing’s disease. Pituitary 2004;7(4):257-64
   PubMedGoogle Scholar
• van der Hoek J, Waaijers M, van Koetsveld PM, Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005;289(2):E278-87
   PubMed Web of Science ®Google Scholar
• Batista DL, Zhang X, Gejman R, The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006;91(11):4482-8
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, Feelders R, The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005;152(4):645-54
   PubMed Web of Science ®Google Scholar
• de Bruin C, Feelders RA, Waaijers AM, Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol 2009;42(1):47-56
   PubMed Web of Science ®Google Scholar
• Boscaro M, Ludlam WH, Atkinson B, Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009;94(1):115-22
   PubMed Web of Science ®Google Scholar
• de Bruin C, Pereira AM, Feelders RA, Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009;94(4):1118-24
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, de Herder WW, Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004;89(5):2452-62
   PubMed Web of Science ®Google Scholar
• Pivonello R, De Martino MC, Cappabianca P, The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009;94(1):223-30
   PubMed Web of Science ®Google Scholar
• Colao A, di Sarno A, Pivonello R, Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002;11(6):787-800
   PubMed Web of Science ®Google Scholar
• Webster J. Clinical management of prolactinomas. Baillieres Best Pract Res Clin Endocrinol Metab 1999;13(3):395-408
   PubMed Web of Science ®Google Scholar
• Jaquet P, Ouafik L, Saveanu A, Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 1999;84(9):3268-76
   PubMed Web of Science ®Google Scholar
• Fusco A, Gunz G, Jaquet P, Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol 2008;158(5):595-603
   PubMed Web of Science ®Google Scholar
• Beck-Peccoz P, Brucker-Davis F, Persani L, Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17(6):610-38
   PubMed Web of Science ®Google Scholar
• Beck-Peccoz P, Persani L, Mantovani S, Thyrotropin-secreting pituitary adenomas. Metabolism 1996;45(8 Suppl 1):75-9
   PubMed Web of Science ®Google Scholar
• Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119(3):236-40
   PubMed Web of Science ®Google Scholar
• Comi RJ, Gesundheit N, Murray L, Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 1987;317(1):12-7
   PubMed Web of Science ®Google Scholar
• Yoshihara A, Isozaki O, Hizuka N, Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocr J 2007;54(1):133-8
   PubMed Web of Science ®Google Scholar
• Filopanti M, Ballare E, Lania AG, Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. J Endocrinol Invest 2004;27(10):937-42
   PubMed Web of Science ®Google Scholar
• Colao A, Filippella M, Di Somma C, Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine 2003;20(3):279-83
   PubMed Web of Science ®Google Scholar
• Florio T, Barbieri F, Spaziante R, Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 2008;15(2):583-96
   PubMed Web of Science ®Google Scholar
• Aparicio T, Ducreux M, Baudin E, Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37(8):1014-9
   PubMed Web of Science ®Google Scholar
• Oberg K, Kvols L, Caplin M, Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15(6):966-73
   PubMed Web of Science ®Google Scholar
• Kulaksiz H, Eissele R, Rossler D, Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50(1):52-60
   PubMed Web of Science ®Google Scholar
• Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17(12):1733-42
   PubMed Web of Science ®Google Scholar
• Cordelier P, Esteve JP, Najib S, Regulation of neuronal nitric-oxide synthase activity by somatostatin analogs following SST5 somatostatin receptor activation. J Biol Chem 2006;281(28):19156-71
   PubMed Web of Science ®Google Scholar
• Ferrante E, Pellegrini C, Bondioni S, Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006;13(3):955-62
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27(28):4656-63
   PubMed Web of Science ®Google Scholar
• de Sa SV, Correa-Giannella ML, Machado MC, Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer 2006;13(1):69-78
   PubMed Web of Science ®Google Scholar
• Unger N, Serdiuk I, Sheu SY, Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin Endocrinol (Oxf) 2008;68(6):850-7
   PubMed Web of Science ®Google Scholar
• Mitra SW, Mezey E, Hunyady B, Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 1999;140(8):3790-6
   PubMed Web of Science ®Google Scholar
• Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000;141(1):111-7
   PubMed Web of Science ®Google Scholar
• Ludvigsen E, Olsson R, Stridsberg M, Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem 2004;52(3):391-400
   PubMed Web of Science ®Google Scholar
• Strowski MZ, Blake AD. Function and expression of somatostatin receptors of the endocrine pancreas. Mol Cell Endocrinol 2008;286(1-2):169-79
   PubMed Web of Science ®Google Scholar
• Singh V, Brendel MD, Zacharias S, Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 2007;92(2):673-80
   PubMed Web of Science ®Google Scholar
• van der Hoek J, van der Lelij AJ, Feelders RA, The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf) 2005;63(2):176-84
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26(13):2124-30
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94(5):1500-8
   PubMed Web of Science ®Google Scholar
• Martin RE, Green LG, Guba W, Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. J Med Chem 2007;50(25):6291-4
   PubMed Web of Science ®Google Scholar